Nordic Life Science
@nordiclifescience.org
Join us for daily news and stories from the Nordic life science industry. Inspiring life science business and innovation. nordiclifescience.org
“We can no longer rely on the US as our primary market. Instead, the EU itself must become willing to pay for innovation and thereby create the conditions for a competitive life science sector here at home,” says Jessica Martinsson, CEO of SwedenBIO.
nordiclifescience.org/new-trump-ca...
nordiclifescience.org/new-trump-ca...
New Trump campaign on tariffs shows that the EU's internal market must be strengthened, states SwedenBIO - NLS
President Trump recently announced that trademarked or patented pharmaceutical products will be subject to a 100 percent tariff starting October 1, 2025 – unless the manufacturer establishes a product...
nordiclifescience.org
September 30, 2025 at 6:29 AM
“We can no longer rely on the US as our primary market. Instead, the EU itself must become willing to pay for innovation and thereby create the conditions for a competitive life science sector here at home,” says Jessica Martinsson, CEO of SwedenBIO.
nordiclifescience.org/new-trump-ca...
nordiclifescience.org/new-trump-ca...
"Denmark and Sweden could not only continue to be innovation drivers and help realize the region’s own potential, but together we could also position ourselves for a place in the driving seat when it comes to the more strategic European ambitions." writes @mediconvalley.bsky.social
Denmark, Sweden, Greater Copenhagen, and the European axis of innovation - NLS
Innovation is obviously a key component of future competitiveness. Consequently, the very same stakeholders from industry, academia.
nordiclifescience.org
September 29, 2025 at 9:05 AM
"Denmark and Sweden could not only continue to be innovation drivers and help realize the region’s own potential, but together we could also position ourselves for a place in the driving seat when it comes to the more strategic European ambitions." writes @mediconvalley.bsky.social
“This support is a very strong vote of confidence in the ability of Swedish and Nordic life sciences to build and compete globally," says Reagan Jarvis, CEO, Anocca. nordiclifescience.org/anocca-raise...
Anocca raises SEK 440 million – Interview with Reagan Jarvis, CEO - NLS
The financing was led by Mellby Gård with strong support from AMF, Ramsbury and existing shareholders, alongside new investors.
nordiclifescience.org
August 18, 2025 at 7:13 AM
“This support is a very strong vote of confidence in the ability of Swedish and Nordic life sciences to build and compete globally," says Reagan Jarvis, CEO, Anocca. nordiclifescience.org/anocca-raise...
Even though many have tried and few succeeded in the quest to find viable treatments for neurodegenerative diseases, Nordic drug developers continue to take different approaches to crack the riddle.
nordiclifescience.org/global-healt...
nordiclifescience.org/global-healt...
Global health & Local efforts: New hope in the neurodegenerative disease pipeline - NLS
Even though many have tried and few succeeded in the quest to find viable treatments for neurodegenerative diseases.
nordiclifescience.org
April 8, 2025 at 7:17 AM
Even though many have tried and few succeeded in the quest to find viable treatments for neurodegenerative diseases, Nordic drug developers continue to take different approaches to crack the riddle.
nordiclifescience.org/global-healt...
nordiclifescience.org/global-healt...
"In the long run, the EU’s life science industry will likely need to reduce its dependence on the U.S. to mitigate the impact of extraordinary events like these. We are being thrown into a chaotic situation reminiscent of the COVID pandemic,” states SwedenBIO
nordiclifescience.org/no-us-market...
nordiclifescience.org/no-us-market...
No US market tariffs on pharmaceuticals – yet - NLS
At a White House press event yesterday, Wednesday April 2, President Trump advanced the next stage of his economic plan by unveiling baseline tariffs of 10% on the vast majority of goods imported to t...
nordiclifescience.org
April 4, 2025 at 7:43 AM
"In the long run, the EU’s life science industry will likely need to reduce its dependence on the U.S. to mitigate the impact of extraordinary events like these. We are being thrown into a chaotic situation reminiscent of the COVID pandemic,” states SwedenBIO
nordiclifescience.org/no-us-market...
nordiclifescience.org/no-us-market...
“Our study shows how different cell types arise from stem cells in the embryo and how they are organized to create important structures in the brain,” stated Emma Andersson, docent at the Department of Cell and Molecular Biology, @ki.se
A family tree for the cells of the nervous system and the inner ear - NLS
Researchers at Karolinska Institutet have developed a method that shows how the nervous system and sensory organs are formed in an embryo.
nordiclifescience.org
April 4, 2025 at 7:33 AM
“Our study shows how different cell types arise from stem cells in the embryo and how they are organized to create important structures in the brain,” stated Emma Andersson, docent at the Department of Cell and Molecular Biology, @ki.se
“Each heart contraction is caused by an influx of calcium into the heart cell. Our agents work by increasing the sensitivity of the heart muscle to this calcium, so that the contraction becomes stronger.” – Patrik Strömberg #AnaCardioAB
Global health & Local efforts: Strengthening the heart - NLS
Cardiovascular diseases have a high mortality rate and although prevention is key, there are many companies, including Nordic ones.
nordiclifescience.org
April 2, 2025 at 6:18 AM
“Each heart contraction is caused by an influx of calcium into the heart cell. Our agents work by increasing the sensitivity of the heart muscle to this calcium, so that the contraction becomes stronger.” – Patrik Strömberg #AnaCardioAB
"EsoBiotec will accelerate and expand the impact of our recent investments and marks a major step forward in realizing our ambition to harness the full potential of cell therapy,” says Susan Galbraith, Executive Vice President, Oncology Haematology R&D, AstraZeneca.
AstraZeneca to acquire EsoBiotec - NLS
EsoBiotec is a biotechnology company focusing on in vivo cell therapies that has demonstrated promising early clinical activity.
nordiclifescience.org
March 17, 2025 at 7:21 AM
"EsoBiotec will accelerate and expand the impact of our recent investments and marks a major step forward in realizing our ambition to harness the full potential of cell therapy,” says Susan Galbraith, Executive Vice President, Oncology Haematology R&D, AstraZeneca.
Overall, 2025 is anticipated to be a year of significant progress, with three key themes standing out, writes Marjo Puumalainen, SwedenBIO.
Trends to follow in 2025 within the life science industry - NLS
As always, JPM kicks off the year as the key event for life science executives to exchange insights and predict the direction of the industry.
nordiclifescience.org
March 12, 2025 at 1:54 PM
Overall, 2025 is anticipated to be a year of significant progress, with three key themes standing out, writes Marjo Puumalainen, SwedenBIO.
“Obesity is the most fascinating lens through which to study life – it spans everything from the micro level of cellular metabolism to the macro level of behavior and society,” says Kirsi Pietiläinen. @helsinki.fi
She is the winner of the EASO-Novo Nordisk Foundation Obesity Prize for Excellence - NLS
Professor Kirsi Pietiläinen receives the Novo Nordisk Foundation prize for her outstanding work in clinical metabolism.
nordiclifescience.org
March 12, 2025 at 1:49 PM
“Obesity is the most fascinating lens through which to study life – it spans everything from the micro level of cellular metabolism to the macro level of behavior and society,” says Kirsi Pietiläinen. @helsinki.fi
Reposted by Nordic Life Science
"The goal is to end the war, establish a just peace, and provide Ukraine with a future perspective for generations to come. We stand by this cause with our voices," writes the Nobel Prize laureates.
131 Nobel Prize laureates sign joint appeal against Russia - NLS
The Nobel Prize laureates protest against Russia's war of invasion and the world's inaction, and they demand that EUR 300 billion in frozen Russian assets be given to Ukraine.
nordiclifescience.org
March 7, 2025 at 1:22 PM
"The goal is to end the war, establish a just peace, and provide Ukraine with a future perspective for generations to come. We stand by this cause with our voices," writes the Nobel Prize laureates.
"To be able to compete globally, we must concentrate our efforts in Europe and build on existing strongholds and clusters of excellence," writes Niels Abel Bonde @mediconvalley.bsky.social
Cutting-edge clusters create competitiveness - NLS
The future of Europe depends on the future of European life science competitiveness. So far, everyone seems to agree.
nordiclifescience.org
March 6, 2025 at 8:36 AM
"To be able to compete globally, we must concentrate our efforts in Europe and build on existing strongholds and clusters of excellence," writes Niels Abel Bonde @mediconvalley.bsky.social
This in vivo study with a novel nasal influenza vaccine candidate is part of Abera Bioscience's collaboration with
CEPI.
CEPI.
Abera announces promising results - NLS
Abera Bioscience reports that its first in vivo study with a novel nasal influenza vaccine candidate has delivered promising results.
nordiclifescience.org
February 13, 2025 at 8:11 AM
This in vivo study with a novel nasal influenza vaccine candidate is part of Abera Bioscience's collaboration with
CEPI.
CEPI.
“Bacterial AMR is such a significant global health issue that we must speed up innovation and try new ways of working together,” says Marianne Holm, Vice President, Infectious diseases, Novo Nordisk Foundation.
Philanthropic partnership launches new initiative to tackle AMR - NLS
The Gates Foundation, Novo Nordisk Foundation, and Wellcome have announced the launch of the Gram-Negative Antibiotic Discovery Innovator.
nordiclifescience.org
February 13, 2025 at 8:05 AM
“Bacterial AMR is such a significant global health issue that we must speed up innovation and try new ways of working together,” says Marianne Holm, Vice President, Infectious diseases, Novo Nordisk Foundation.
Christopher Goodnow @garvaninstitute.bsky.social and David Nemazee @scripps.edu discovered important mechanisms that prevent B cells from attacking the body’s own tissues in autoimmune disease. This could pave the way for new treatments for rheumatoid arthritis, lupus and multiple sclerosis.
The 2025 Crafoord Prize laureates - NLS
The Crafoord Prize in Polyarthritis 2025, worth SEK six million, is awarded to Christopher Goodnow, Australia, and David Nemazee, USA.
nordiclifescience.org
January 30, 2025 at 9:35 AM
Christopher Goodnow @garvaninstitute.bsky.social and David Nemazee @scripps.edu discovered important mechanisms that prevent B cells from attacking the body’s own tissues in autoimmune disease. This could pave the way for new treatments for rheumatoid arthritis, lupus and multiple sclerosis.
The team behind NordicRWE believe the possibilities of Real-World Evidence are obvious, but access to and sharing data between the Nordic countries are hurdles that need to be overcome.
Breaking new ground: Real-World Evidence - NLS
The team behind NordicRWE believe the possibilities of Real-World Evidence are obvious, but access to and sharing data.
nordiclifescience.org
January 29, 2025 at 9:18 AM
The team behind NordicRWE believe the possibilities of Real-World Evidence are obvious, but access to and sharing data between the Nordic countries are hurdles that need to be overcome.
The investment in Canada will create more than 700 high-skilled jobs, across all areas of the business. @astrazeneca.bsky.social
AstraZeneca plans USD 570 million investment in Canada - NLS
The investment in Canada will create more than 700 high-skilled jobs, across all areas of the business.
nordiclifescience.org
January 24, 2025 at 8:32 AM
The investment in Canada will create more than 700 high-skilled jobs, across all areas of the business. @astrazeneca.bsky.social
“This is what scientific progress in medicine is intended to achieve: improving the life of patients, in particular those with rare diseases, by providing innovative therapeutic options.” – Fredrik Sjöö Nordic Region CSL Behring #GeneTherapy
First Danish patients treated with gene therapy for haemophilia B - NLS
CSL Behring Denmark has announced that the first Danish patients with haemophilia B were treated with the gene therapy HEMGENIX.
nordiclifescience.org
January 21, 2025 at 8:41 AM
“This is what scientific progress in medicine is intended to achieve: improving the life of patients, in particular those with rare diseases, by providing innovative therapeutic options.” – Fredrik Sjöö Nordic Region CSL Behring #GeneTherapy
"This open-source approach enables researchers to utilize our data and publish their findings, enabling scientific progress,” says Cecilia Lindskog #TheHumanProteinAtlas
Breaking new ground: Biological databases - NLS
The Human Protein Atlas, one of the world’s largest biological databases, gives us a more profound understanding of protein expression.
nordiclifescience.org
January 20, 2025 at 10:05 AM
"This open-source approach enables researchers to utilize our data and publish their findings, enabling scientific progress,” says Cecilia Lindskog #TheHumanProteinAtlas
Hopeful! Preclinical data have shown a marked reduction of endometriotic lesions and pain following treatment with vipoglanstat. @gesyntapharma.bsky.social #endometriosis
Gesynta Pharma raises SEK 304 million - NLS
Gesynta Pharma has secured SEK 304 million in a Series B financing round led by Innovestor Life Science.
nordiclifescience.org
January 20, 2025 at 10:02 AM
Hopeful! Preclinical data have shown a marked reduction of endometriotic lesions and pain following treatment with vipoglanstat. @gesyntapharma.bsky.social #endometriosis
"This MOU will strengthen formally that relationship, building a bridge between the innovative life science communities in Sweden and California,” says Joe Panetta, president emeritus of Biocom California.
SwedenBIO and Biocom Californa sign MOU - NLS
SwedenBIO and Biocom have signed a memorandum of understanding (MOU) to undertake cooperative activities they state.
nordiclifescience.org
January 14, 2025 at 8:28 AM
"This MOU will strengthen formally that relationship, building a bridge between the innovative life science communities in Sweden and California,” says Joe Panetta, president emeritus of Biocom California.
According to Professor Matthias Christandl, Leader of the Quantum for Life Centre #CopenhagenUniversity, the potential of quantum computing within life sciences is enormous and in order to take the lead, investments in both quantum hardware and software is essential.
Breaking new ground: Quantum computing - NLS
According to Professor Matthias Christandl, the potential of quantum computing within life sciences is enormous.
nordiclifescience.org
January 13, 2025 at 10:15 AM
According to Professor Matthias Christandl, Leader of the Quantum for Life Centre #CopenhagenUniversity, the potential of quantum computing within life sciences is enormous and in order to take the lead, investments in both quantum hardware and software is essential.
Go Finland! "A strong collective will has emerged, uniting various stakeholders in a shared mission to build something remarkable," writes Alexandra Peth, Finnish Bioindustries.
Reinventing Finland - NLS
A strong collective will has emerged during these challenging times. The Finnish economy has had difficulties achieving robust growth.
nordiclifescience.org
December 20, 2024 at 11:38 AM
Go Finland! "A strong collective will has emerged, uniting various stakeholders in a shared mission to build something remarkable," writes Alexandra Peth, Finnish Bioindustries.
"I think what underlies our achievements is an incredible ecosystem in Sweden. We’re very excited now with the capital that we have obtained to advance our lead program into late stage clinical development for idiopathic pulmonary fibrosis," says Ahmed Mousa, CEO, Vicore Pharma.
Vicore Pharma is the winner of SwedenBIO Award - NLS
Vicore Pharma is praised for being at the forefront of addressing unmet medical needs in rare diseases and for securing.
nordiclifescience.org
December 13, 2024 at 8:10 AM
"I think what underlies our achievements is an incredible ecosystem in Sweden. We’re very excited now with the capital that we have obtained to advance our lead program into late stage clinical development for idiopathic pulmonary fibrosis," says Ahmed Mousa, CEO, Vicore Pharma.